Friday, May 17, 2013

• FDA Sets 17 July 2013 For MOXDUO® Advisory Committee Meeting --- SYDNEY and BEDMINSTER, N.J., May 17, 2013
  Posted at 6:00 AM
  QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the US Food and Drug Administration (FDA) has set 17 July 2013 as the date of the Advisory Committee meeting to consider the Company's resubmitted MOXDUO( )New Drug Application (NDA). "The timing is within the expected date range of late June to late July," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "Formal notification of the Advisory Committee date finalises the sequence of events which lead to ... read more
• Syncsort Launches a New, Intuitive Website ... Find Smarter Solutions to Today's Data Integration and Data Protection Challenges --- WOODCLIFF LAKE, N.J., May 17, 2013
  Posted at 6:00 AM
  Syncsort, a global leader in Big Data integration and high-performance data protection solutions, today announced the launch of its new, more intuitive website. Syncsort.com has been redesigned to make it easier for customers to find the right content and see how Syncsort software offerings deliver smarter data solutions to customers. (Logo: http://photos.prnewswire.com/prnh/20000922/SYNCSORTLOGO ) "45 years ago, Syncsort revolutionized data processing on the mainframe. Today, we are bringing to market ground-breaking new approaches to Hadoop data integration and for managing and protecting data ... read more
• IBM Cited as a Leader in Business Consulting Services Worldwide --- ARMONK, N.Y., May 17, 2013
  Posted at 6:00 AM
  IBM (NYSE: IBM) today announced that IT analyst firm International Data Corporation (IDC) named IBM Global Business Services as a leader in the IDC Marketscape: Worldwide Business Consulting Services 2013 Vendor Analysis. (Logo: http://photos.prnewswire.com/prnh/20090416/IBMLOGO) Based on an evaluation framework that incorporates interviews with more than 600 business consulting buyers worldwide, IBM was ranked the most capable among all providers in driving innovation in a world being transformed by data. These clients viewed IBM as the most capable at helping them ... read more
• Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment --- FARMINGTON, Conn., May 17, 2013
  Posted at 5:55 AM
  The escalation of new biological drugs, including antibodies and recombinant proteins, is placing renewed emphasis on alternate delivery technologies. Alternate delivery technologies are on the rise as a number of factors are converging to create both risk and opportunity for pharmaceutical makers and their delivery device partners. These include new classes of drugs for previously refractory conditions, the growing trend toward self-administration for chronic diseases, shifting patient demographics in industrial countries, caregiver safety legislation, and continued pressure to control healthcare ... read more
• Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis --- PALO ALTO, Calif., May 17, 2013
  Posted at 5:44 AM
  Cellular Biomedicine Group (OTCQB: CBMG) today announced that it has achieved 50% enrollment of the total projected enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of the medical technology haMPC (Human Adipose-derived Mesenchymal Progenitor Cells) therapy for Knee Osteoarthritis (KOA). To date the trial has had no Severe Adverse Effect (SAE) reported. The Phase I open label clinical research trial for KOA, registered with the U.S. National Institutes of Health (NIH) under number NCT01809769 (click ... read more
• Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference --- RIDGEFIELD, Conn., May 17, 2013
  Posted at 5:35 AM
  Boehringer Ingelheim will contribute to advancing the scientific discussion in respiratory disease at the American Thoracic Society International Conference (ATS 2013) in Philadelphia, PA, May 17 - 22.( )Data will highlight research conducted with a product approved for the treatment of chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® (tiotropium bromide inhalation powder)], as well as investigational compounds for asthma, idiopathic pulmonary fibrosis (IPF) and COPD. The breadth of Boehringer Ingelheim data at ATS 2013, one of the largest gatherings of pulmonary ... read more
• RecommendMe.tv Launches New Educational Business Program Featuring Camille Smith --- SANTA CRUZ, Calif., May 17, 2013
  Posted at 5:30 AM
  RecommendMe.tv launches interactive business education platform with featured speaker and executive coach Camille Smith. The new educational program is the first in a series of planned events scheduled for June 2013. The first program called "Understanding your Performance Style & Ambitions" was announced on Recommend Me TV's weekly BlogTalkRadio show, which airs live Wednesdays from noon - 1 p.m. (Photo: http://photos.prnewswire.com/prnh/20130517/PH15919-a )(Photo: http://photos.prnewswire.com/prnh/20130517/PH15919-b ) "We are thrilled to introduce this new program featuring Camille Smith. Camille has created a spectacular program ... read more
• Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd --- MIAMI LAKES, Fla., May 17, 2013
  Posted at 5:30 AM
  Fuse Science, Inc. (OTCQB: DROP), (www.fusescience.com) a consumer products and delivery technology company that is developing new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals, announced today that it will hold a business update teleconference and webcast for shareholders and the investment community on Wednesday, May 22(nd), 2013 at 4:30 PM ET. Fuse Science, Inc. CEO, Brian Tuffin will host the call and will be joined by Rubin Hanan, President and COO and Jeanne Hebert, ... read more
• Ecommerce Loss Prevention Specialist eFraud Security Selected by Ajax Union to Help Protect Its Online Transactions --- NEW YORK, May 17, 2013
  Posted at 5:30 AM
  eFraud Security, a service provider of Online Credit Card Fraud Verifications, announced that it will partner with online marketing company, Ajax Union. eFraud Security will use its CardProber AutoResolver(TM) to help Ajax Union's large network of more than 47,000 online merchants mitigate losses resulting from purchases using stolen credit card numbers. The company, available at http://www.eFraudSecurity.com, offers a host of services, including chargebacks, order verification, and loss prevention. (Logo: http://photos.prnewswire.com/prnh/20130517/PH15882LOGO ) Ajax Union will utilize eFraud Security's CardProber AutoResolver(TM) solution. AutoResolver provides ... read more
• Vertex Calls for Redemption of $400 Million in Convertible Senior Subordinated Notes Due 2015 --- CAMBRIDGE, Mass.
  Posted at 5:30 AM
  

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that it has called for redemption of its outstanding $400.0 million in aggregate principal amount of 3.35% Convertible Senior Subordinated Notes due 2015, pursuant to the provisional “soft call” redemption right in the indenture ... read more
• XenoPort Provides Update on Availability of Horizant --- SANTA CLARA, Calif.
  Posted at 5:30 AM
  

  XenoPort, Inc. (Nasdaq: XNPT) announced today that shipments of Horizant® (gabapentin enacarbil) Extended-Release Tablets to its distributor in the United States have commenced. Depending on individual pharmacy ordering patterns, the product is anticipated to be generally available to patients in the first week of June. ... read more
• Impax Laboratories Launches Authorized Generic of Zomig (zolmitriptan) Tablets and Orally Disintegrating Tablets in the U.S. --- HAYWARD, Calif.
  Posted at 5:30 AM
  

  Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig® (zolmitriptan) tablets and orally disintegrating tablets, 2.5 mg and 5 mg, in the U.S., as part of a Distribution, License, Development and Supply Agreement with AstraZeneca ... read more
• Data on Cook Medical Products Presented at Digestive Disease Week® --- ORLANDO, Fla.
  Posted at 5:00 AM
  

  At this week’s Digestive Disease Week (DDW), the world’s largest gathering of physicians and researchers in the gastroenterology field, six abstracts and other clinical data will be presented on Cook Medical products. Cook’s EchoTip® ProCore™ High Definition Ultrasound Biopsy needles are featured in many of these ... read more
• Tech Council of Maryland Names GlycoMimetics CEO Rachel King as 2013 Executive of the Year --- GAITHERSBURG, Md.
  Posted at 5:00 AM
  

  GlycoMimetics, Inc. announced today that the Tech Council of Maryland (TCM) named Rachel K. King, GlycoMimetics Chief Executive Officer, as the winner of its 2013 Executive of the Year award. Ms. King was honored last night at the TCM's 25th Annual Tech ... read more
• Alnylam Presents Key Pre-Clinical Proof-of-Concept Data for ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinate Synthase-1 (ALAS-1) for the Treatment of Porphyria --- CAMBRIDGE, Mass.
  Posted at 5:00 AM
  

  Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has presented key pre-clinical proof-of-concept data from its RNAi therapeutic program targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of porphyria including acute intermittent porphyria (AIP). The ... read more
• Celsion's ThermoDox® HEAT Study Findings Reviewed at the 9th Annual World Conference on Interventional Oncology (WCIO) --- LAWRENCEVILLE, N.J., May 17, 2013
  Posted at 5:00 AM
  Celsion Corporation (NASDAQ: CLSN) announced today that Professor Riccardo Lencioni, MD, FSIR, EBIR, 2013 WCIO Program Chairman and the Director of the Division of Diagnostic Imaging and Intervention at Pisa University School of Medicine in Italy and Lead European Principal Investigator for the HEAT Study and Professor Ronnie T.P. Poon, MD, MS, PhD, FRCS(Edin), FACS, Professor of Surgery at the University of Hong Kong and Lead Asia Pacific Principal Investigator for the HEAT Study conducted separate scientific discussions reviewing the ... read more
• Transition to Propellant-Free Combivent® Respimat® (ipratropium bromide and albuterol) Inhalation Spray Nears Completion --- RIDGEFIELD, Conn., May 17, 2013
  Posted at 5:00 AM
  As part of the company's commitment to chronic obstructive pulmonary disease (COPD) patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals (HCPs) and patients that the transition to COMBIVENT(®) RESPIMAT(® )(ipratropium bromide and albuterol) Inhalation Spray for the maintenance treatment of COPD is nearly complete. Distribution of COMBIVENT (ipratropium bromide and albuterol sulfate) Inhalation Aerosol (COMBIVENT MDI) will cease in May, and once the supply runs out, COMBIVENT RESPIMAT will be the only COMBIVENT product ... read more
• Source Financial Launches WikiPay Payment Network --- LOS ANGELES, May 17, 2013
  Posted at 5:00 AM
  Source Financial, Inc. (OTCQB: SRCF) ("Source Financial", or "the Company") today announces the availability of the WikiPay Payment Network at www.wikipay.com, a proprietary mobile and online cash-based money transfer and payment service ("WikiPay"). WikiPay enables all consumers, banked or unbanked, with any PC or mobile device to send money for $1.00 on any phone, anytime, anywhere. "We have succeeded in building the fastest, most efficient, secure and inexpensive payment network by eliminating the legacy that has plagued the US banking ... read more
• Catapult Systems Continues Expansion Plans within the Washington, D.C. Area --- AUSTIN, Texas, May 17, 2013
  Posted at 4:30 AM
  Catapult Systems is excited to announce that Reed Parker has joined our Washington, D.C. business unit. He will assume the role of General Manager and will be responsible for leading and growing both Catapult's Federal and Commercial Microsoft-focused lines of business. Reed's background and leadership experience will be instrumental in Catapult's expansion plans in the D.C. area. "We welcome Reed's knowledge and expertise to our D.C. practice," said Sam Goodner, CEO of Catapult Systems. "He brings with him ... read more
• Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy --- MIAMI, May 17, 2013
  Posted at 4:30 AM
  Insero Health, Inc., a company developing natural compounds to address unmet medical needs in epilepsy and related neurological disorders, is today reporting top-line results from a Phase Ib trial of its lead compound INS001 in patients with drug-resistant epilepsy. The data are being presented at the AntiEplileptic Drug and Device Trials (AED) Xll meeting by Dr. Steven Schachter, Harvard Medical School epileptologist and Chairman of Insero's Scientific Advisory Board. In this study, INS001 appeared safe and well tolerated. INS001 ... read more